Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression

PURPOSE: Define volumetric tumor growth rate in advanced NSCLC patients with sensitizing EGFR mutations initially treated with EGFR-TKI therapy beyond progression. METHODS: The study included 58 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nishino, Mizuki, Dahlberg, Suzanne E., Cardarella, Stephanie, Jackman, David M., Rabin, Michael S., Ramaiya, Nikhil H., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3817609/
https://ncbi.nlm.nih.gov/pubmed/23922022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados